S Nirala1, Y Wang, Y-Z Peng, P Yang, T Guo. 1. Department of Cardiology, 1st Affiliated Hospital of the KMU (Kunming Medical University), Kunming, Yunnan, P.R. China. sanjunirala@hotmail.com.
Abstract
OBJECTIVE: Almost all the past CSWT studies show the beneficial effects on CAD patients in a maximum duration of 1-year follow-up. The aim of this study was to evaluate the actual CSWT effects in 6 years follow-up period. PATIENTS AND METHODS: The subjects were selected exclusively on the basis of inclusion criteria. The total number of patients was 52, out of which control group (n = 11) and the shock wave group (SW group, n = 41) was selected. RESULTS: The wall motion, MPI, nitrate dosage, NYHA classification, SAQ scores, CCS grading, 6 MWT were markedly improved in the long-term (6 years) follow-up for SW group than the control group. CONCLUSIONS: Following 6 years of follow-up, the CSWT provided agreeable results that improved myocardial function and quality of life in comparing to the month 0 and the control group. These outcomes advise that on a long-term (72 months) CSWT shows better parameters than the control group. These findings highlight that CSWT can improve clinical symptoms, morphology, functions of the heart and quality of life in patients with CHD than the patients just on drug therapy for a long-term.
RCT Entities:
OBJECTIVE: Almost all the past CSWT studies show the beneficial effects on CAD patients in a maximum duration of 1-year follow-up. The aim of this study was to evaluate the actual CSWT effects in 6 years follow-up period. PATIENTS AND METHODS: The subjects were selected exclusively on the basis of inclusion criteria. The total number of patients was 52, out of which control group (n = 11) and the shock wave group (SW group, n = 41) was selected. RESULTS: The wall motion, MPI, nitrate dosage, NYHA classification, SAQ scores, CCS grading, 6 MWT were markedly improved in the long-term (6 years) follow-up for SW group than the control group. CONCLUSIONS: Following 6 years of follow-up, the CSWT provided agreeable results that improved myocardial function and quality of life in comparing to the month 0 and the control group. These outcomes advise that on a long-term (72 months) CSWT shows better parameters than the control group. These findings highlight that CSWT can improve clinical symptoms, morphology, functions of the heart and quality of life in patients with CHD than the patients just on drug therapy for a long-term.
Authors: Greta Burneikaitė; Evgeny Shkolnik; Jelena Čelutkienė; Gitana Zuozienė; Irena Butkuvienė; Birutė Petrauskienė; Pranas Šerpytis; Aleksandras Laucevičius; Amir Lerman Journal: Cardiovasc Ultrasound Date: 2017-04-12 Impact factor: 2.062
Authors: Jelena Čelutkienė; Greta Burneikaitė; Evgeny Shkolnik; Gabrielius Jakutis; Donatas Vajauskas; Kamilė Čerlinskaitė; Gitana Zuozienė; Birutė Petrauskienė; Roma Puronaitė; Renata Komiagienė; Irena Butkuvienė; Rima Steponėnienė; Jonas Misiūra; Aleksandras Laucevičius Journal: Cardiovasc Ultrasound Date: 2019-07-04 Impact factor: 2.062